Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019 : Benefits and risks of antithrombotic therapy for cardiovascular disease prevention
Walker, Jaqui (International Aspirin Foundation)
Cattaneo, Marco (Università degli studi di Milano)
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau)
Agnelli, Giancarlo (University of Perugia)
Chan, Andrew T. (Harvard Medical School)
Lanas, Angel (Universidad de Zaragoza)
Rocca, Bianca (Catholic University School of Medicine)
Rothwell, Peter (Centre for the Prevention of Stroke and Dementia)
Patrignani, Paola ('G.d'Annunizio' University)
Langley, Ruth (MRC Clinical Trials Unit at UCL)
Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau)
Cosentino, Francesco (Karolinska University Hospital and Karolinska Institutet (Suecia))
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. Getting the best evidence to support real-life decisions in the clinic can be complex, and individualising management in order to balance both the risks and benefits of different disease prevention strategies appears to be the best approach. It is hoped that future decision-making tools and biomarkers will help direct treatments at those most likely to benefit.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Anticoagulant ; Antiplatelet ; Antithrombotic ; Aspirin ; Benefit ; Cardiovascular disease (CVD) ; Colorectal cancer (CRC) ; Diabetes mellitus (DM) ; Gastroprotectant agents ; Optimizing aspirin dose ; Precision medicine ; Primary prevention ; Risk ; Secondary prevention ; Targeting ; Upper gastrointestinal (GI) bleeding
Published in:	ecancermedicalscience, Vol. 14 (13 2020) , p. 998, ISSN 1754-6605

DOI: 10.3332/ECANCER.2019.998
PMID: 32153653

24 p, 1.1 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles